At a glance
- Corifollitropin alfa is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 138 publications mentioning it, including 31 randomized controlled trials and 3 animal-only studies.
- ClinicalTrials.gov lists 72 registered studies testing it (5 active).
- FDA's adverse event system (FAERS) holds 58 reports mentioning it; 57 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Corifollitropin alfa versus daily recombinant FSH for ovarian stimulation in women of advanced maternal age: a cost-minimization analysis in an out-of-pocket setting.
- The two-shot protocol. A randomized controlled trial of a novel two-injection ovarian stimulation strategy.
- Corifollitropin alfa N02 versus recombinant FSH for ovarian stimulation: a phase 3 trial and safety study in Chinese women.
- An injection-lite approach to ovarian stimulation in poor responder patients using corifollitropin alfa and nasal GnRH agonist.
- Gonadotrophin type and antral follicle count-adjusted follicular recruitment and oocyte yield in 4525 antagonist cycles.
- Influence of corifollitropin alfa on embryo morphokinetics and fertility treatment outcome.
- Risk of progesterone elevation in patients with low ovarian reserve using long-acting FSH IVF protocol: a randomized controlled trial.
- Feasibility and efficacy of random-start progestin-primed ovarian stimulation: a multicenter pilot randomized controlled trial in oocyte donation.
- A single dose of corifollitropin alfa is equipotent to a daily dose of 300 IU recombinant FSH regardless of ovarian reserve.
- Etonogestrel implant for LH suppression in a novel DuoStim ovarian stimulation protocol using overlapping doses of corifollitropin alfa for social egg freezing: a case report.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 72
- Active
- 5
- With posted results
- 18
Conditions studied
Show 40 more studies
All 72 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 58
- Serious
- 57
- With death outcome
- 1
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.